{
    "clinical_study": {
        "@rank": "119600", 
        "brief_summary": {
            "textblock": "This phase II study will be conducted to:\n\n        1. evaluate the pharmacokinetics, safety, tolerance, and efficacy of different dosing\n           schedules of Posaconazole in immunocompromised hosts with a variety of refractory\n           invasive fungal infections or in subjects who require empiric antifungal therapy and\n\n        2. identify the dosing schedule that provides the most consistent therapeutic drug\n           exposure in this patient population."
        }, 
        "brief_title": "PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)(COMPLETED)", 
        "condition": "Mycoses", 
        "condition_browse": {
            "mesh_term": "Mycoses"
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, randomized, parallel group, study of pharmacokinetics, safety,\n      tolerance, and efficacy of Posaconazole in the treatment of immunocompromised hosts with\n      refractory invasive fungal infections or in subjects who require empiric antifungal therapy.\n\n      The projected number of subjects planned for enrollment is 100 evaluable subjects. The\n      number of planned study sites is approximately ten in the United States and approximately\n      eight in the rest of the world."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A proven, either probable or possible invasive fungal infection which is refractory\n             to standard antifungal therapies.\n\n          -  Subjects who received >72 hours of systemic empiric antibacterial therapy and are\n             neutropenic (<500 neutrophils per mm3 and, have had fever that has reached an oral\n             temperature >38c (or >100.4f)twice in the last 48 hours, or have a recurrence of\n             fever (oral temperature, >38c or >100.4F) while receiving broad spectrum\n             antibacterial therapy after prior resolution of fever while on antibacterial therapy.\n\n          -  Able to take oral medication or take medication via enteral feeding tube."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "100", 
        "firstreceived_date": "May 1, 2002", 
        "id_info": {
            "nct_id": "NCT00034671", 
            "org_study_id": "P01893"
        }, 
        "intervention": {
            "intervention_name": "Posaconazole oral suspension", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Posaconazole"
        }, 
        "keyword": [
            "Aspergillosis, Candidiasis, Mucormycosis, Cryptococcosis", 
            "Invasive Fungal Infections"
        ], 
        "lastchanged_date": "May 20, 2013", 
        "official_title": "Phase II Study of Safety, Tolerance, Efficacy, and Pharmacokinetics of Posaconazole (SCH 56592) for the Treatment of Invasive Fungal Infections in Immunocompromised Hosts", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2002", 
            "@type": "Actual"
        }, 
        "removed_countries": {
            "country": [
                "United States", 
                "Germany"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00034671"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2000", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }, 
    "geocoordinates": {}
}